Literature DB >> 2805621

D-penicillamine in the therapy of ankylosing spondylitis.

K Tytman, K Bernacka, S Sierakowski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2805621     DOI： 10.1007/bf02030361

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  6 in total

1.  [Letter: Ankylosing spondylarthritis. Failure of treatment by D-penicillamine].

Authors:  A P Leca; J P Camus
Journal:  Nouv Presse Med       Date:  1975-01-11

2.  Failure of D-penicillamine to affect peripheral joint involvement in ankylosing spondylitis or HLA B27-associated arthropathy.

Authors:  H A Bird; A S Dixon
Journal:  Ann Rheum Dis       Date:  1977-06       Impact factor: 19.103

Review 3.  D-penicillamine: chemistry and clinical use in rheumatic disease.

Authors:  H E Howard-Lock; C J Lock; A Mewa; W F Kean
Journal:  Semin Arthritis Rheum       Date:  1986-05       Impact factor: 5.532

4.  Penicillamine in ankylosing spondylitis: a double blind placebo controlled trial.

Authors:  M M Steven; M Morrison; R D Sturrock
Journal:  J Rheumatol       Date:  1985-08       Impact factor: 4.666

5.  HLA antigens and toxic reactions to sodium aurothiopropanol sulphonate and D-penicillamine in patients with rheumatoid arthritis.

Authors:  P Perrier; C Raffoux; P Thomas; J N Tamisier; M Busson; A Gaucher; F Streiff
Journal:  Ann Rheum Dis       Date:  1985-09       Impact factor: 19.103

6.  [Ankylosing spondylitis. Pathogenesis and therapy].

Authors:  D P Mertz
Journal:  Fortschr Med       Date:  1981-03-19
  6 in total
  2 in total

Review 1.  Current guidelines for the drug treatment of ankylosing spondylitis.

Authors:  E Toussirot; D Wendling
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

2.  Ankylosing spondylitis. Current drug treatment.

Authors:  J T Gran; G Husby
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.